Disclaimer Notice:

Dear Readers! I started this blog when my daughter was in the NICU. She had ventriculitis. Her CSF report grew E.coli. But, she was injected Teicoplanin directly into her brain. The doctors made two errors here:

Teicoplanin is for gram-positive bacteria only. It does not treat E.coli.
Teicoplanin is not for intraventricular use. The manufacturer strongly discourage injecting Teicoplanin into the brain.

My daughter bled into the brain. She lived for another two years and ultimately died.

The information provided on Emedz.net is for doctors and pharmacists only to manage their patients in the best way and avoid medications-related errors.

Still, for the general population, this should not be considered professional medical advice or a substitute for consultation with a licensed healthcare provider. The content on this blog is not intended to diagnose, treat, cure, or prevent any disease or health condition.

Always seek the advice of a qualified healthcare professional before making any changes to your diet, exercise routine, medication, or any other aspect of your healthcare. We strongly discourage self-medication and self-treatment.

Even though the primary author of emedz.net is an experienced health professional, the blog is not intended to replace medical advice sought at the Doctor’s Clinic.

The authors share personal experiences, research findings, and general knowledge about health and wellness and medications-related topics.

However, individual health situations vary, and what works for one person may not work for another. It's important to consult with a healthcare provider for personalized guidance.

We strive to provide accurate and up-to-date information, but medical knowledge is constantly evolving. Therefore, we do not guarantee the accuracy, completeness, or timeliness of the information presented in this blog.

Emedz.net is not an online pharmacy:

Online pharmacies sell medicines and pharmaceutical products. EMEDZ.net is intended to provide drug-related information to pharmacists and physicians. It is intended to provide authentic information about medicines so as to prevent errors related to prescriptions.

We do not sell medicines, so please don’t ask for them.

We are not affiliated with any pharmaceutical companies:

Emedz.net has no affiliation with any pharmaceutical companies. We do not promote any product. Sometimes brand names are also mentioned in the title of the page, but that is what is called a “Featured Image”. It has nothing to do with selling or promoting that brand. Just to make things easier, generic and brands are mentioned in the blog.

Emedz.net may contain links to external websites or resources for your convenience. We do not endorse or take responsibility for the content of these external sites.

In no event shall Emedz.net, its authors, contributors, or any related parties be liable for any damages or consequences arising from the use of the information provided on this blog.

By using Emedz.net, you acknowledge and agree to this disclaimer and our Terms of Use. If you do not agree with this disclaimer or our Terms of Use, we advise you to refrain from using our website.

Remember, your health is a valuable asset, and decisions about your health should always be made in consultation with a qualified healthcare professional.

Sevoflurane - Uses, Dose, MOA, Brands, Side effects

An inhalational anaesthetic called sevoflurane is used to induce and maintain general anaesthesia.

Sevoflurane Uses:

Anesthesia:
- Used for both inpatient and outpatient surgery in adults and children to initiate and maintain general anaesthesia

Sevoflurane Dose in Adults

Sevoflurane Dose in Anesthesia:

Inhalation:
- With or without the use of nitrous oxide, concentrations between 0.5% and 3% are often needed to reach surgical levels of anaesthesia; 0.6% is the level at which amnesia and loss of awareness start to happen.
MAC values for surgical levels of anesthesia:
- 25 years:
  - Sevoflurane in oxygen: 2.6%
  - Sevoflurane in 65% N 0/35% oxygen: 1.4%
- 40 years:
  - Sevoflurane in oxygen: 2.1%
  - Sevoflurane in 65% N 0/35% oxygen: 1.1%
- 60 years:
  - Sevoflurane in oxygen: 1.7%
  - Sevoflurane in 65% N 0/35% oxygen: 0.9%
- 80 years:
  - Sevoflurane in oxygen: 1.4%
  - Sevoflurane in 65% N 0/35% oxygen: 0.7%

Sevoflurane Dose in Children

Sevoflurane Dose in Anesthesia:

Inhalation:
- With or without the use of nitrous oxide, concentrations between 0.5% and 3% are often needed to reach surgical levels of anaesthesia; 0.6% is the level at which amnesia and loss of awareness start to happen.
MAC values for surgical levels of anesthesia:
- 0 to 1-month-old full-term neonates:
  - Sevoflurane in oxygen: 3.3%
- 1 to <6 months:
  - Sevoflurane in oxygen: 3%
- 6 months to <1 year:
  - Sevoflurane in oxygen: 2.8%
  - Sevoflurane in 65% N 0/35% oxygen: 2%
- 1 to <3 years:
  - Sevoflurane in oxygen: 2.8%
  - Sevoflurane in 60% N 0/40% oxygen: 2%
- 3 to 12 years:
  - Sevoflurane in oxygen: 2.5%

Pregnancy Risk Category: B

It can also cross the placenta.
Results from animal studies demonstrate that prolonged or recurrent use of general anaesthetics and sedative drugs that block N-methyl D-aspartate receptors (NMDA) and/or inhibit gamma-aminobutyric acid can have an impact on brain development (GABA). The third trimester is the most dangerous for human foetuses.
It's critical to weigh the advantages and disadvantages of sevoflurane medication for expectant mothers, especially for procedures lasting more than three hours.
It has been reported that Sevoflurane can be used in obstetrical anesthesia.
Avoiding maternal exposure is important as it can cause uterine relaxation and fetal depress. There have been no adverse reactions to general anesthesia used for elective c section delivery.
Regardless of the trimester, ACOG advises pregnant women to not object to medically necessary surgeries or procedures.
Non-urgent surgery should not be performed during the second trimester. Avoid elective surgery until after delivery.

Use while breastfeeding

Sevoflurane may or may not be found in breast milk.
However, it is quickly washed out so its levels are unlikely to be of any clinical significance 1 day after anesthesia.
The Academy of Breast Feeding Medicine recommends postponing elective surgery until your child is more mature and established in breastfeeding.
When possible, express milk should be used before surgery.
A healthy, full-term baby can resume breastfeeding or express milk once she is awake and well.
Save milk for vulnerable children to use later when they are at lower risk.

Dose in Kidney Disease:

No dosage adjustments have been provided in the manufacturer's labeling; use cautiously in patients with creatinine >1.5 mg/dL (safety not established).

Dose in Liver disease:

No dosage adjustments have been provided in the manufacturer's labeling; use cautiously. The safety in patients with severe hepatic impairment has not been studied

Common Side Effects of Sevoflurane:

Cardiovascular:
- Hypotension
Central Nervous System:
- Agitation
Gastrointestinal:
- Nausea
- Vomiting
Respiratory:
- Cough

Less Common Side Effects of Sevoflurane:

Cardiovascular:
- Tachycardia
- Bradycardia
- Hypertension
Central Nervous System:
- Drowsiness
- Shivering
- Dizziness
- Headache
- Hypothermia
- Myoclonus
- Delirium
Gastrointestinal:
- Sialorrhea
Respiratory:
- Airway Obstruction
- Laryngospasm
- Breath-Holding
- Apnea
Miscellaneous:
- Fever

Contraindications to Sevoflurane:

Hypersensitivity to sevoflurane or other halogenated painkillers, or any component in the formulation
Malignant hyperthermia susceptibility (known or suspected).

Canadian labeling: Additional contraindications not in US labeling

Previous administrations of halogenated anesthetics have caused liver dysfunction, jaundice or unexplained febrile illness, such as leukocytosis or eosinophilia.
Contraindications to general anesthesia

Warnings and precautions

Agitation/delirium
- You should monitor for any emergence agitation, delirium or other symptoms.
Hepatic effects
- Rarely, hepatitis post-operatively or hepatic dysfunction may occur with or without jaundice. The risk of developing a halogenated hydrocarbon anesthetic reaction is higher if you have had previous exposure.
Hyperkalemia
- Pediatric patients have experienced perioperative hyperkalemia on occasion. Some cases, although not all, have involved the use of inhaled anaesthetics.
- Latent and overt neuromuscular diseases (eg Duchenne muscular dystrophy) were the most vulnerable. Other abnormalities include elevated CPK or myoglobinuria. Monitor closely for arrhythmias. Recognize and treat hyperkalemia and resistive arrhythmias immediately.
Hypotension
- A dose-dependent decrease in blood pressure can occur during maintenance anesthesia. This may be more rapid than other inhaled anesthetics.
Increased intracranial pressure
- Vasodilation of the cerebral vasculature may occur, and in some cases, it may raise intracranial pressure.
Malignant hyperthermia
- The onset of malignant hyperthermia is possible. There have been some reported fatal cases. It is not advised for patients to use this medication if they have specific hereditary mutations in the ryanodine receptor.
Extension of QT
- Several studies have linked sevoflurane to QT prolongation (some fatal). In patients who have a high risk of QT prolongation, exercise cautious.
Respiratory depression
- It is possible to develop dose-dependent respiratory depression, blunted ventilatory responses to hypoxia or hypercapnia, and dose-dependent respiratory depression. This can cause a decrease in hypoxic pulmonary vasoconstriction, which can lead to an increase in pulmonary shunt.
Heart Failure:
- The American Heart Association has stated that sevoflurane may be an agent that can exacerbate myocardial dysfunction.
Hepatic impairment
- Patients with severe hepatic impairment should be cautious. It is not known if the drug is safe in patients with severe liver impairment.
Renal impairment
- Patients with kidney impairment (ie creatinine >1.5 mg/dL) should be cautious.
- It has not been proven safe for patients with severe renal impairment.
Seizure disorder
- Patients at high risk of seizures should be treated with caution Children and young adults may experience seizures.

Sevoflurane: Drug Interaction

Risk Factor C (Monitor therapy)
Alcohol (Ethyl)	Alcohol's CNS depressing effect may be amplified by CNS depressants (Ethyl).
Alfuzosin	The hypotensive effects of blood pressure-lowering medications may be strengthened.
Alizapride	CNS depressants may have an enhanced CNS depressant impact.
Antipsychotic Agents (Second Generation [Atypical])	Blood Pressure Lowering Agents may enhance the hypotensive effect of Antipsychotic Agents (Second Generation [Atypical]).
Barbiturates	May enhance the hypotensive effect of Blood Pressure Lowering Agents.
Benperidol	May enhance the hypotensive effect of Blood Pressure Lowering Agents.
Blood Pressure Lowering Agents	May enhance the hypotensive effect of Hypotension-Associated Agents.
Brexanolone	Brexanolone's CNS depressing effects may be amplified by other CNS depressants.
Brimonidine (Topical)	May enhance the CNS depressant effect of CNS Depressants.
Brimonidine (Topical)	May enhance the hypotensive effect of Blood Pressure Lowering Agents.
Bromopride	May enhance the CNS depressant effect of CNS Depressants.
Cannabidiol	May enhance the CNS depressant effect of CNS Depressants.
Cannabis	May enhance the CNS depressant effect of CNS Depressants.
Chlorphenesin Carbamate	May enhance the adverse/toxic effect of CNS Depressants.
CNS Depressants	May enhance the adverse/toxic effect of other CNS Depressants.
Diazoxide	May enhance the hypotensive effect of Blood Pressure Lowering Agents.
Dimethindene (Topical)	May enhance the CNS depressant effect of CNS Depressants.
Doxylamine	May enhance the CNS depressant effect of CNS Depressants. Management: The manufacturer of Diclegis (doxylamine/pyridoxine), intended for use in pregnancy, specifically states that use with other CNS depressants is not recommended.
Dronabinol	May enhance the CNS depressant effect of CNS Depressants.
DULoxetine	Blood Pressure Lowering Agents may enhance the hypotensive effect of DULoxetine.
EPINEPHrine (Nasal)	The arrhythmogenic effects of inhaled anaesthetics may be increased (Nasal).
EPINEPHrine (Oral Inhalation)	The arrhythmogenic effects of inhaled anaesthetics may be increased (Oral Inhalation).
Esketamine	CNS depressants may have an enhanced CNS depressant impact.
Fenoterol	Fenoterol's ability to induce arrhythmias may be enhanced by inhalational anaesthetics.
Formoterol	The arrhythmogenic impact of formoterol may be enhanced by inhalational anaesthetics.
Haloperidol	QT-prolonging Agents (Indeterminate Risk - Caution) may enhance the QTcprolonging effect of Haloperidol.
Herbs (Hypotensive Properties)	May enhance the hypotensive effect of Blood Pressure Lowering Agents.
HydrOXYzine	May enhance the CNS depressant effect of CNS Depressants.
Hypotension-Associated Agents	Blood Pressure Lowering Agents may enhance the hypotensive effect of Hypotension-Associated Agents.
Isoniazid	May decrease the serum concentration of CYP2E1 Substrates (High risk with Inhibitors). Specifically, it may decrease CYP2E1 substrate serum concentrations below baseline after isoniazid discontinuation. Isoniazid may increase the serum concentration of CYP2E1 Substrates (High risk with Inhibitors).
Kava Kava	CNS depressants' harmful or toxic effects could be increased.
Levodopa-Containing Products	Levodopa-Containing Products' hypotensive effects may be strengthened by blood pressure-lowering medications.
Lofexidine	CNS depressants may have an enhanced CNS depressant impact. Management: Separate drug interaction monographs go into further detail about the medications indicated as exceptions to this book.
Lormetazepam	The hypotensive effects of blood pressure-lowering medications may be strengthened.
Magnesium Sulfate	CNS depressants may have an enhanced CNS depressant impact.
MetyroSINE	The sedative effects of metyroSINE may be strengthened by CNS depressants.
Minocycline	CNS depressants may have an enhanced CNS depressant impact.
Mirtazapine	CNS Depressants may enhance the CNS depressant effect of Mirtazapine.
Molsidomine	May enhance the hypotensive effect of Blood Pressure Lowering Agents.
Nabilone	May enhance the CNS depressant effect of CNS Depressants.
Naftopidil	May enhance the hypotensive effect of Blood Pressure Lowering Agents.
Neuromuscular-Blocking Agents (Nondepolarizing)	The neuromuscular-blocking impact of neuromuscular-blocking agents may be enhanced by inhaled anaesthetics (Nondepolarizing)
Nicergoline	The hypotensive effects of blood pressure-lowering medications may be strengthened.
Nicorandil	The hypotensive effects of blood pressure-lowering medications may be strengthened.
Nitroprusside	Nitroprusside's hypotensive impact may be strengthened by blood pressure-lowering medications.
Pentoxifylline	The hypotensive effects of blood pressure-lowering medications may be strengthened.
Pholcodine	Pholcodine's hypotensive impact may be strengthened by blood pressure lowering medications.
Phosphodiesterase 5 Inhibitors	The hypotensive effects of blood pressure-lowering medications may be strengthened.
Piribedil	Piribedil's CNS depressing effects may be enhanced by other CNS depressants.
Pramipexole	The sedative effects of pramipexole might be enhanced by CNS depressants.
Prostacyclin Analogues	The hypotensive effects of blood pressure-lowering medications may be strengthened.
QT-prolonging Agents (Highest Risk)	The QTc-prolonging action of QT-prolonging Agents may be enhanced by QT-prolonging Agents (Indeterminate Risk - Caution) (Highest Risk). When using these medications together, watch out for cardiac arrhythmias and a prolonged QTc interval. Individuals may be considerably more at risk for QTc prolongation if they have additional risk factors.
Quinagolide	The hypotensive effects of blood pressure-lowering medications may be strengthened.
Ritodrine	May enhance the adverse/toxic effect of Inhalational Anesthetics.
ROPINIRole	CNS Depressants may enhance the sedative effect of ROPINIRole.
Rotigotine	CNS Depressants may enhance the sedative effect of Rotigotine.
Rufinamide	May enhance the adverse/toxic effect of CNS Depressants. Specifically, sleepiness and dizziness may be enhanced.
Selective Serotonin Reuptake Inhibitors	CNS Depressants may enhance the adverse/toxic effect of Selective Serotonin Reuptake Inhibitors. Specifically, the risk of psychomotor impairment may be enhanced.
Tetrahydrocannabinol	May enhance the CNS depressant effect of CNS Depressants.
Tetrahydrocannabinol and Cannabidiol	May enhance the CNS depressant effect of CNS Depressants.
Trimeprazine	May enhance the CNS depressant effect of CNS Depressants.
Risk Factor D (Consider therapy modification)
Amifostine	Blood Pressure Lowering Agents may enhance the hypotensive effect of Amifostine. Management: When amifostine is used at chemotherapy doses, blood pressure lowering medications should be withheld for 24 hours prior to amifostine administration. If blood pressure lowering therapy cannot be withheld, amifostine should not be administered.
Bambuterol	May enhance the arrhythmogenic effect of Inhalational Anesthetics. Management: Some labels recommend specifically avoiding halothane; others recommend separating administration by at least 6 hours; other bambuterol labels do not mention this possible interaction.
Blonanserin	CNS Depressants may enhance the CNS depressant effect of Blonanserin.
Buprenorphine	CNS Depressants may enhance the CNS depressant effect of Buprenorphine. Management: Consider reduced doses of other CNS depressants, and avoiding such drugs in patients at high risk of buprenorphine overuse/self-injection. Initiate buprenorphine at lower doses in patients already receiving CNS depressants.
Chlormethiazole	May enhance the CNS depressant effect of CNS Depressants. Management: Monitor closely for evidence of excessive CNS depression. The chlormethiazole labeling states that an appropriately reduced dose should be used if such a combination must be used.
CYP2E1 Inhibitors (Strong)	May decrease the metabolism of CYP2E1 Substrates (High risk with Inhibitors).
Droperidol	CNS depressants may have an enhanced CNS depressant impact. Consider lowering the dosage of droperidol or other CNS drugs (such as opioids or barbiturates) when they are used concurrently. In separate drug interaction monographs, exceptions to this monograph are covered in more detail.
EPINEPHrine (Systemic)	The arrhythmogenic effects of inhaled anaesthetics may be increased (Systemic). Treatment: When treating patients who are now receiving or have just had inhalational anaesthetics, provide epinephrine with extra caution. Employ epinephrine at lower dosages than usual and keep an eye out for the emergence of cardiac arrhythmias.
Flunitrazepam	CNS Depressants may enhance the CNS depressant effect of Flunitrazepam.
HYDROcodone	CNS Depressants may enhance the CNS depressant effect of HYDROcodone. Management: Avoid concomitant use of hydrocodone and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug.
Methotrimeprazine	CNS Depressants may enhance the CNS depressant effect of Methotrimeprazine. Methotrimeprazine may enhance the CNS depressant effect of CNS Depressants. Management: Reduce adult dose of CNS depressant agents by 50% with initiation of concomitant methotrimeprazine therapy. Further CNS depressant dosage adjustments should be initiated only after clinically effective methotrimeprazine dose is established.
Obinutuzumab	The hypotensive effects of blood pressure-lowering medications may be strengthened. Management: Take into account temporarily stopping blood pressure-lowering drugs 12 hours before the start of the obinutuzumab infusion and keeping them off until 1 hour after the infusion is finished.
Opioid Agonists	CNS Depressants may enhance the CNS depressant effect of Opioid Agonists. Management: Avoid concomitant use of opioid agonists and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug.
OxyCODONE	CNS Depressants may enhance the CNS depressant effect of OxyCODONE. Management: Avoid concomitant use of oxycodone and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug.
Perampanel	May enhance the CNS depressant effect of CNS Depressants. Management: Patients taking perampanel with any other drug that has CNS depressant activities should avoid complex and high-risk activities, particularly those such as driving that require alertness and coordination, until they have experience using the combination.
Sodium Oxybate	May enhance the CNS depressant effect of CNS Depressants. Management: Consider alternatives to combined use. When combined use is needed, consider minimizing doses of one or more drugs. Use of sodium oxybate with alcohol or sedative hypnotics is contraindicated.
Suvorexant	CNS Depressants may enhance the CNS depressant effect of Suvorexant. Management: Dose reduction of suvorexant and/or any other CNS depressant may be necessary. Use of suvorexant with alcohol is not recommended, and the use of suvorexant with any other drug to treat insomnia is not recommended.
Tapentadol	May enhance the CNS depressant effect of CNS Depressants. Management: Avoid concomitant use of tapentadol and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug.
Zolpidem	CNS Depressants may enhance the CNS depressant effect of Zolpidem. Management: Reduce the Intermezzo brand sublingual zolpidem adult dose to 1.75 mg for men who are also receiving other CNS depressants. No such dose change is recommended for women. Avoid use with other CNS depressants at bedtime; avoid use with alcohol.
Risk Factor X (Avoid combination)
Azelastine (Nasal)	CNS Depressants may enhance the CNS depressant effect of Azelastine (Nasal).
Bromperidol	Blood Pressure Lowering Agents may enhance the hypotensive effect of Bromperidol. Bromperidol may diminish the hypotensive effect of Blood Pressure Lowering Agents.
Bromperidol	May enhance the CNS depressant effect of CNS Depressants.
Dexmethylphenidate	May enhance the hypertensive effect of Inhalational Anesthetics.
DOPamine	DOPamine's ability to induce arrhythmias may be enhanced by inhalational anaesthetics. Management: Patients receiving halogenated hydrocarbon anaesthetics should not be given dopamine. Watch for arrhythmia if concurrent treatment cannot be avoided. Based on studies from animals, propranolol may be able to reverse ventricular arrhythmia caused by dopamine.
Ephedra	Can make inhalational anaesthetics more arrhythmogenic.
EPHEDrine (Nasal)	Can make inhalational anaesthetics more arrhythmogenic.
EPHEDrine (Systemic)	Can make inhalational anaesthetics more arrhythmogenic.
Isoproterenol	Can make inhalational anaesthetics more arrhythmogenic.
Metaraminol	Anesthetics for inhalation may increase the arrhythmogenic potential of metaraminol.
Methylphenidate	Inhalational anaesthetics' tendency to cause hypertension may be enhanced.
Norepinephrine	Norepinephrine's ability to induce arrhythmias may be enhanced by inhalational anaesthetics.
Orphenadrine	Orphenadrine's CNS depressant effects may be amplified by CNS depressants.
Oxomemazine	CNS depressants may have an enhanced CNS depressant impact.
Paraldehyde	The CNS depressing effects of paraldehyde may be enhanced by CNS depressants.
Thalidomide	The CNS depressing effect of thalidomide may be enhanced by CNS depressants.

Monitoring parameters:

Blood pressure
Temperature,
Heart rate and rhythm
O2 saturation
Monitor end-tidal CO2 and end-tidal sevoflurane concentrations prior to and throughout anesthesia
The temperature of CO2 absorbent canister

How to administer Sevoflurane?

Use caution when administering sevoflurane in low-flow or closed-circuit systems since it is unstable and may release potentially harmful breakdown products. Sevoflurane-specific calibrated vaporizers are utilised for this purpose.

Mechanism of action of Sevoflurane:

Inhaled anesthetics can cause alteration of the activity neuronal ion channel activity, particularly fast synaptic neurotransmitter receivers (nicotinic Acetylcholine and GABA receptors).
The effects of sevoflurane on sympathetic stimulation, including the cardiovascular system, are very limited.
Sevoflurane does not cause respiratory irritation or circulatory stimulation. The drug may cause myocardial contractility to decrease, and systemic vascular resistance to decrease.
Blood pressure and sympathetic nerve activity may drop as a result.
Sevoflurane has an immediate start and quick recovery because of its low blood/gas partition coefficient.

The onset of action: Induction time is within 2 to 3 minutes

Duration:

Time to emerge: Determined by blood concentration at the time sevoflurane is stopped. Because to sevoflurane's limited blood gas solubility, the anaesthetic concentration in the lung changes quickly (0.63).
While anaesthesia lasts less than two hours, sevoflurane's 90% decrement time (the amount of time needed for an anaesthetic concentration in vessel-rich tissues to fall by 90%) is brie

Metabolism: In liver (~5%) via CYP2E1

Excretion: Exhaled gases

International Brand Names of Sevoflurane:

Sojourn
Amasevo
Floves
Haluran
Sefether
Sevo
Sevocris
Sevodex
Sevofran
Sevofrane
Sevoran
Sevorane
Sevotan
Sojourn
Sovener
Ultane

Sevoflurane Brand Names in Pakistan:

Brands will be updated later.

Disclaimer Notice:

Emedz.net is not an online pharmacy:

We are not affiliated with any pharmaceutical companies:

Sevoflurane - Uses, Dose, MOA, Brands, Side effects

Sevoflurane Uses:

Anesthesia:

Sevoflurane Dose in Adults

Sevoflurane Dose in Anesthesia:

Inhalation:

MAC values for surgical levels of anesthesia:

Sevoflurane Dose in Children

Sevoflurane Dose in Anesthesia:

Inhalation:

MAC values for surgical levels of anesthesia:

Pregnancy Risk Category: B

Use while breastfeeding

Dose in Kidney Disease:

Dose in Liver disease:

Common Side Effects of Sevoflurane:

Cardiovascular:

Central Nervous System:

Gastrointestinal:

Respiratory:

Less Common Side Effects of Sevoflurane:

Cardiovascular:

Central Nervous System:

Gastrointestinal:

Respiratory:

Miscellaneous:

Contraindications to Sevoflurane:

Warnings and precautions

Agitation/delirium

Hepatic effects

Hyperkalemia

Hypotension

Increased intracranial pressure

Malignant hyperthermia

Extension of QT

Respiratory depression

Heart Failure:

Hepatic impairment

Renal impairment

Seizure disorder

Monitoring parameters:

How to administer Sevoflurane?

Mechanism of action of Sevoflurane:

International Brand Names of Sevoflurane:

Sevoflurane Brand Names in Pakistan:

Recent Posts

Related Posts